

St Stephen's AIDS Trust  
**Clinical Research Publications 2008 – 2014**

**St Stephen's Centre, 369 Fulham Road, London SW10 9NH**

**Tel: 020 3315 6136**

**[www.ssat.org.uk](http://www.ssat.org.uk)**

Registered Charity: **11034163**

Registered in England Company Number: **7134218**

# INTRODUCTION

**The St Stephen's AIDS Trust is a UK clinical research charity based at the Chelsea and Westminster Hospital in London.**

The Charity was founded in 1991 by Professor Brian Gazzard and a team of colleagues in response to the HIV/AIDS global pandemic and its impact on people effected by and living with HIV in the United Kingdom.

**St Stephen's AIDS Trust mission statement is to:**

*"promote clinical research into the treatment of HIV and those infections and malignancies associated with the acquired immunodeficiency syndrome (AIDS), in particular the research undertaken at the Chelsea and Westminster Hospital, and to publish such research. It also promotes education regarding all aspects and matters relating to HIV by providing information, training and advice throughout the world".*

Over the last 30 years the Charity has been at the forefront of clinical research studies, from the early nucleoside reverse transcriptase inhibitor studies in the 1980s, to the current range of successful highly active anti-retroviral therapy studies. The Charity's research activities have produced, in the last 10 years alone, over 500 clinical research papers. A selection of some 300 of these papers has been collected together in this publication.

Charity has developed a strong track record in clinical research through the continued investment in its research infrastructure and capability, such as its dedicated Phase I-IV PK and Clinical Trials Unit at the Chelsea and Westminster Hospital. As well as these physical facilities, the Charity has the capability to sponsor and manage multi-centred clinical research studies, in the UK and internationally, through its established service teams in regulatory, compliance, project management, logistics, data management and statistics. A range of leading medical and scientific experts in HIV medicine, immunology and infectious diseases supports this infrastructure and capability in clinical research.

As the selection of papers included in this publication suggest, the Charity has successfully managed a diverse range of relationships and partnerships. These include many international pharmaceutical companies; a number of influential global NGO's (Bill and Melinda Gates Foundation, International AIDS Vaccine Initiative); key UK public research bodies (MRC, NHR, Public Health); academic institutions from the UK and across the world; and, as equally important, individual researchers, scientists and clinicians.

---

If you are interested in finding out more about the work of the Charity, exploring possible clinical research collaborations and partnerships or accessing its managed services for conducting clinical research in the UK and internationally, please contact:

**General (Charity) enquiries:** Linda Connor, Admin Manager: 020 3315 6136

**PK and Clinical Trials Unit:** Carl Fletcher, Associate Director: 020 3325 6325

**Clinical Research Organisation Services:** Ruth Bateson, Associate Director: 020 3315 6563

2014

Writing group. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshal N, Nelson M, Orkin C, Paton N, Philips, Post F, Pozniak A, Sabin C, Trelvelion R, Ustianowski A, Waalsh J, Waters L, Wilkins E, Winston A, Youle M

**British HIV Association Guidelines for the treatment of HIV 1 positive adults with Antiretroviral therapy 2012 (updated 2013)**

*HIV Med 2014 Mar; 15 suppl 2. 1-9*

Parikh ND, Martel-Laferriere V, Kushner T, Childs K, Vachon ML, Dronamraj D, Taylor C, Fiel MI, Schaino T, Nelson M, Agarwal K, Dieterich DT

**Clinical factors that predict noncirrhotic portal hypertension in HIV infected patients: Proposed diagnostic algorithm**

*J Infect Dis 2014 Mar; 209 (5): 734-8*

Chacko L, Chamberlain F, Mandalia S, Nelson M

**Do resistance patterns vary between different FTC contain drug regimens?**

*J Infect 2014 Feb 8 2014*

McFaul K, Liptrott N, Cox A, Martin P, Egan D, Owen A, Kelly S, Karolia Z, Shaw K, Bower M & Boffito M.

**Evolution of cellular and viral resistance in HIV patients diagnosed with lymphoma receiving chemotherapy and combination antiretroviral therapy.**

*HIV Medicine 2014, 15 (suppl 3) 53*

Chacko L, Chamberlain F, Mandalia S, Nelson M

**Five-year safety evaluation of Maraviroc in HIV 1 infected treatment experienced patients**

*J Acqui Immune Defic Syndr 2014 Jan 1; 65 (1): 78-81*

Nightingale A, Ratcliffe D, Leonidou L, Margetts A, Asboe D, Gazzard B, Catalan J, Barber TJ.

**HIV-related neurocognitive impairment screening: the patient's perspective on its utility and psychological impact.**

*AIDS Care. 2014 Mar 13*

Dhoot S, Balachandran K, Tittle V, Bunker C, Nelson M, Kelleher P & Bower M

**Immunological function in HIV-seronegative men who have sex with men (MSM) and Kaposi's sarcoma (KS)**

*HIV Medicine 2014, 15 (suppl 3) 55.*

May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick D, Martin F, Hill T, Walsh J, Post Fisher M, Ainsworth J, Jose S, Leen C, Nelson M, Anderson J, Sabin C: for the UK Collaborative HIV cohort (UK CHIC) study

**Impact on life expectancy of HIV 1 positive individuals of CD4+ cell count and Viral load response to antiretroviral therapy: UK cohort study**

*AIDS 2014 Feb 19*

Longley J, Redlin S, Balachandran K, Holmes P, Nelson M & Bower M.

**Non-Hodgkin's lymphoma (NHL): Does being on cART before diagnosis make a difference?**

*HIV Medicine 2014, 15 (suppl 3) 55*

Tull T, Papineni P, Cook C, Mee J, Bower M, Morar N, Nelson M

**Paraneoplastic pemphigus in patient infected with HIV**

*Clin Exp Dermatol. 2014 Jan ; 39 (1): 83-5*

Raman L, Nelson M

**Prospective stage stratified approach to AIDS related Kaposi's Sarcoma**

*J Clin Virol 2014 Feb 2*

Smith M, Pealing J, McCann S, Balachandran K, Nelson M & Bower M

**Second malignancies in patients with Kaposi's sarcoma (KS): Does systemic chemotherapy contribute to risk?**

*HIV Medicine 2014, 15 (suppl 3) 8.*

Keay R, Singh G, Abdul-Latif M, Rayment M, Nelson M

**Shigella flexneri enteritis in risk- taking HIV infected MSM**

*J Infect 2014 Jan; 68 (1); 103-4*

Ferras Alwan, Annie He, Silvia Montoto, Shireen Kassam, Matthew Mee, Fiona Burns, Simon Edwards, Andy Wilson, Melinda Tenant-Flowers, Robert Marcus, Kirit M. Ardeshta, Mark Bower, Kate Cwynarski.

**The addition of Rituximab to CODOX-M/IVAC chemotherapy in the treatment of Burkitt lymphoma is safe and associated with increased efficacy in the HIV positive population.**

*EHA 2014.*

Bulteel N, Bansa-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Nelson M, CHIC study group; UK Drug resistant Database (UK HDRD) Study Group

**The emergence of drug resistant HIV variants at virological failure of HAART combination containing efavirenz, Tenofovir and lamivudine or emtricitabine within the UK collaborative HIV cohort**

*J Infect 2014 Jan; 68 (1): 77-84*

2013

Jackson A, Kløverpris HN, Boffito M, Handley A, Atkins M, Hayes P, Gilmour J, Riddell L, Chen F, Bailey-Tippets M, Walker B, Ackland J, Sullivan M, Goulder P

**A Randomised, Placebo-Controlled, First-In-Human Study of a Novel Clade C Therapeutic Peptide Vaccine Administered Ex Vivo to Autologous White Blood Cells in HIV Infected Individuals.**

*PLoS One.* 2013;17.

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M, Team A.

**96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.**

*Antivir Ther.* 2013 Jul 31

Pozniak AL, Arribas JR.

**A benchmark for management of drug resistant HIV.**

*Lancet Infect Dis.* 2013 Jul;13(7):561-2

Kassam S, Bower M, Lee SM, de Vos J, Fields P, Gandhi S, Nelson M, Montoto S; Tennant-Flowers M, Burns F, Marcus R, Edwards SG, Cwynarski K

**A retrospective multi-centre analysis of treatment intensification for HIV positive patients with high risk diffuse large B cell lymphoma**

*Leuk Lymphoma* 2013 Sep; 54 (9): 1921-7

Martin TC, Martin NK, Naresh KN, Nelson M

**A traumatic splenic rupture secondary to chronic HIV infection**

*Int J STD AIDS* 2013 Dec; 24 (12) 989-91

Revell AD, Wang D, Wood R, Morrow C, Templeman H, Hamers R, Alvarez-Uria G, Streinu-Cercel A, Ebe L, Wensing A, Reiss P, van Sigham AI, Nelson M, Emery S, Montanr JSm, Lane HC, Larder BA; on behalf of RDI group

**An update to the HIV - TrePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes**

*J Antimicrob Chemother* 2013 Nov 24

Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D, Kingston MA, Thng C, McCormack S, Gill ON, Nardone A;

**Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England**

*Sex Transm Infect* 2013; 89:404-8

Rayment M, Doku E, Thornton A, Pearn M, Sudhanva M, Jones R, Nardone A, Roberts P, Tenant-Flowers M, Anderson J, Sullivan AK and Mark Atkins

**Automatic Oral Fluid-Based HIV Testing in HIV Screening Programmes**

*HIV Med* 2013; 14 Suppl 3:49-52

Abdel Malek R, Cox S, Bower M, Farag D & Alsirafy S.

**Availability of informal caregivers for palliative care patients with cancer: Is there a difference between higher and lower income settings?**

*Eur J Cancer*, 2013: 49/S2, S291.

Mehta P, Nelson M, Brand A, Boag F

**Avascular necrosis in HIV**

*Hematol Int.* 2013 Jan; 33 (1): 235-8

Girad PM, Nelson M, Mohammed P, Hill A, van Delft Y, Moecklinghoff C

**Can we stop CD4+ testing in patients with HIV 1 RNA suppression on antiretroviral treatment?**

*AIDS* 2013 Nov 13; 27 (17): 2759-63

Jagit Singh GK, Ijaz S, Rockwood N, Farnworth SP, Devitt E, Atkins M, Tedder R, Nelson M.

**Chronic Hepatitis E as a cause for cryptogenic cirrhosis in HIV**

*J. Infect* 2013 Jan; 66 (1): 103-6

Moyle G, Else L, Jackson A, Back D, Yapa MH, Seymour N, Ringner-Nackter L, Karolia Z, Gazzard B, Boffito M

**Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics**

*Antimicrob Agents Chemother.* 2013;57:3640-4.

Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, Dejesus E, Antunes F, Arastéh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK

**Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1-Infected Patients: Week 48 Results.**

*J Infect Dis.* 2013;208:32-9

Bower M, Della Pria A, Flook M, Hayward K, Januszewski A, Williams J & Nelson M

**Comparison of two diagnostic criteria schemes for multicentric Castleman's disease in 72 cases.**

*HIV Medicine* 2013, 14 (suppl 2) 28

## 2013 continued

Revell AD, Wang D, Wood R, Morrow C, Templeman H, Hamers RL, Alvarez-Uria G, Steinu-Cercel A, Ene L, Wensing AM, DeWolf F, Nelson M, Montaner JS, Lane HC, Larder BA, RDI study group

**Computation models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource limited settings**

*J Antimicrob Chemother* 2013 June; 68 (6); 1406-14

Raben D, Delpech V, de Wit J, Sullivan A, Lazarus J, Dedes N, Coenen T, Lundgren J;

**Conclusions from the HIV in Europe Copenhagen 2012 Conference and ways forward: working together for optimal HIV testing and earlier care**

*HIV Med* 2013; 14 Suppl 3:1-5

Rice B, Elford J, Yin Z, Kruijshaar M, Abubakar I, Lipman M, Pozniak A, Kall M, Delpech V.

**Decreasing incidence of tuberculosis among heterosexuals living with diagnosed HIV in England and Wales.**

*AIDS*. 2013 Apr 24;27(7):1151-7.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team.

**Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study**

*Lancet*. 2013 Aug 24;382(9893):700-8.

Beckett H, Abdul-Latif M, Mandalia S, Singh GKJ, Bower M & Nelson M.

**Effect of bisphosphonates on the treatment of BMD abnormalities in an HIV-1 infected cohort**

*HIV Medicine* 2013, 14 (suppl 2) 39

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B; Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C; Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C

**Effects of age on antiretroviral plasma drug concentration in HIV infected subjects undergoing routine therapeutic drug monitoring**

*J Antimicrob Chemother* 2013 June 68 (6) 1354-9

Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA, Kaplan R, Lazzarin A, Valdez H, Goodrich J, Mori J, Craig C, Tawadrous M

**Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial**

*J Acquir Immune Defic Syndr*. 2013 Feb 1;62(2):171-9

Nithianathan V, Singh GKJ, Bower M & Nelson M

**Emerging patterns of integrase inhibitor resistance**

*HIV Medicine* 2013, 14 (suppl 2) 24

O'Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R, Mackie N, Anderson J, Orkin C, Nelson M, Kegg S, Leen C, Palfreeman A, Post F, Johnson M, Sabin CA, Phillips AN

**Failure to achieve a CD4+ cell count response in combination antiretroviral therapy despite consistent viral load suppression**

*AIDS* 2013 Dec 11

Rayment M, Sullivan AK

**Failure to test for HIV infection; A medicolegal question?**

*Casebook* 2013 21; 1: 7

Sullivan AK, Raben D, Reekie J, Rayment M, Mocroft A, Esser S, Leon A, Begovac J, Brinkman K, Zangerle R, Grzeszczuk A, Vassilenko A, Hadziosmanovic V, Krasnov M, Sönnernborg A, Clumeck N, Gatell J, Gazzard B, Monforte Ad, Rockstroh J, Lundgren JD

**Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study)**

*PLoS One* 2013; 8(1):e52845. *Epub* 2013 Jan 15

Lewitsching S, Gedela K, Toby M, Kulasegaram R, Nelson M, O'Doherty M, Cook GJ

**F-FDG PET/CT in HIV related central nervous system pathology**

*Eur J Nucl Med Mol Imaging* 2013 Sept; 40 (9); 1420 -7

Vispo E, Cevik M, Rockstroh JK, Barreiro P, Nelson M, Scourfired A, Wasmuth JC, Boesecke C, Soriano V, European Network of Clinic Trials (NEAT)

**Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV infected patients**

*Clin Infect Dis* 2013 April; 56 (8): 1117 - 22

Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D, Kingston MA, Thng C, McCormack S, Gill ON, Nardone A; GUMNet.

**Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England**

*Sex Transm Infect* 2013; 89:404-8

C. Cevik M, Oh K, Scott S, Tan J, Bower M & Nelson M

**Hepatic safety profile of antiretrovirals in individuals infected with HIV and chronic hepatitis**

*HIV Medicine* 2013, 14 (suppl 2) 70

Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R; Gazzard BG, Nelson M

**Hepatitis C Virus reinfection incidence and treatment outcomes among HIV positive MSM**

*AIDS* 2013 Oct 23; 27 (16): 2551-7

Coutinho R, Flook M, Dalla Pria A, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A, Tenant-Flowers M, Marcus R, Orkin C, Gribben JG, Montoto S, Bower M

**HIV status does not influence the outcome of patients diagnosed with DLBCL treated with R-CHOP in the HAART era**

*Haematologica*, 2013; 98 (s1) 129.

Pozniak A, Rackstraw S, Deayton J, Barber T, Taylor S, Manji H, Melvin D, Croston M, Nightingale S, Kulasegaram R, Pitkanen M, Winston A.

**HIV-associated neurocognitive disease: case studies and suggestions for diagnosis and management in different patient sub-groups.**

*Antivir Ther.* 2013 Mar 21

Lawton MD, Nathan M, Asboe D.

**HPV vaccination to prevent anal cancer in men who have sex with men**

*Sex Transm Infect.* 2013 Aug;89(5):342-3.

Barton SE and OMahoney C

**HPV vaccination; reaping the rewards of the appliance of science.**

*BMJ* 2013;346:f2184

Van de Velde V, Nelson M, Bower M & Sonecha S.

**Indications for changing to raltegravir therapy in patient sixth pre-existing undetectable viral load**

*HIV Medicine* 2013, 14 (suppl 2) 61

Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D, Cummins N, Dalmau D, Dehovitz J, Lehmann C, Sullivan A, Woolley I, Kuller L, Neaton JD, Tracy RP

**INSIGHT SMART Study Team. HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation.**

*J Am Heart Assoc* 2013; 2(4):e000264

Bashford J, Nelson M, Bower M, Atkins M

**JC - a forgotten foe or a foe to be forgotten**

*IV Med* 2013 May; 14 (5): 326

Gathogo EN, Hamzah L, Hilton R, Marshall N, Ashley C, Harber M, Levy JB, Jones R, Boffito M, Khoo SH, Drage M, Bhagani S, Post FA

**Kidney transplantation in HIV-positive adults: The UK experience.**

*Int J STD AIDS.*

Bull L, Bower M & Nelson M.

**Long-term therapeutic success of etravirine in switch and naive patients.**

*HIV Medicine* 2013, 14 (suppl 2) 57

Herasimtschuk AA, Hansen BR, Langkilde A, Moyle GJ, Andersen O, Imami N

**Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy.**

*Clin Exp Immunol.* 2013;173:444-53

Hughes G, Alexander S, Simms I, Conti S, Ward H, Powers C, Ison C; on behalf of the LGV Incident Group.

**Lymphogranuloma venereum diagnoses among men who have sex with men in the UK: interpreting a cross-sectional study using an epidemic phase-specific framework.**

*Sex Transm Infect* 2013 Jul 12

Sullivan AK, Savage EJ, Lowndes CM, Paul G, Murphy G, Carne S, Back DJ, Gill ON

**Non-disclosure of HIV status in UK sexual health clinics - a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey**

*Sex Transm Infect* 2013; 89:120-1. *Epub* 2013 Feb 13

Martin TC, Scourfield A, Rockwood N, Martin NK, Patel N, Nelson M; Gazzard BG

**Pancreatic insufficiency in patients with HIV infection:role of didanosine questioned**

*HIV Med* 2013 March; 14 (3): 161-6



## 2013 continued

Della Pria A, Holmes P, Alfa-Wali M, Fox P, McKenna H, Nelson M & Bower M

**Persistence of anal dysplasia following chemoradiotherapy for anal cancer**

*HIV Medicine* 2013, 14 (suppl 2) 28

Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, Dunn DT; for the UK Collaborative Group on HIV Drug Resistance.

**Persistence of HIV-1 Transmitted Drug Resistance Mutations**

*J Infect Dis.* 2013 ;208(9):1459-63.

Revell AD, Alvarez-Uria G, Wang D, Pozniak A, Montaner JS, Lane HC, Larder BA

**Potential Impact of a Free Online HIV Treatment Response Prediction System for Reducing Virological Failures and Drug Costs after Antiretroviral Therapy Failure in a Resource-Limited Setting.**

*Biomed Res Int.* 2013;2013:579741.

Cevik M, Dickinson L, Singh GS, Bower M & Nelson M

**Raltegravir (RAL) switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals.**

*HIV Medicine* 2013, 14 (suppl 2) 71.

Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guy B, Williams S, Chuck S, Vanveggel S, Deck H, Stevens M

**Rilpivirine versus efavirenz in HIV1 infected subjects receiving emtricitabine/Tenofovir DF: pooled 96 week data from ECHO and THRIVE studies**

*HIV Clin Trials* 2013 May-June; 14 (3): 81-91

Rayment M, Rae C, Ghooloo F, Doku E, Hardie J, Finlay S, Gidwani S, Atkins M, Roberts P, Sullivan AK.

**Routine HIV Testing in the Emergency Department: Tough Lessons in Sustainability**

*HIV Med* 2013; 14 Suppl 3:6-9

The HSV 040 Vaccine Study Group

**Safety and Immunogenicity of a glycoprotein D genital Herpes subunit vaccine in healthy 10-17 years of age. Results from a randomised controlled double blind trial.**

*Vaccine* 2013 July 9. S0264-410X(13. 891-8

Hayes P, Gilmour J, von Lieven A, Gill D, Clark L, Kopycinski J, Cheeseman H, Chung A, Alter G, Dally L, Zachariah D, Lombardo A, Ackland J, Sayeed E, Jackson A, Boffito M, Gazzard B, Fast PE, Cox JH, Laufer D

**Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults**

*Clin Vaccine Immunol.* 2013 ;20:397-408.

Alfa-Wali M, Safarfashandi L, Ion L, Nelson M, Allen-Mersh T & Bower M.

**Salvage surgery for residual primary anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals.**

*HIV Medicine* 2013, 14 (suppl 2) 28

Bull L, Bower M & Nelson M.

**Salvage therapy with protease inhibitor sparing regimens containing etravirine**

*HIV Medicine* 2013, 14 (suppl 2) 60.

Barber TJ, Bradshaw D, Hughes D, Leonidou L, Margetts A, Ratcliffe D, Thornton S, Pozniak A, Asboe D, Mandalia S, Boffito M, Davies N, Gazzard B, Catalan J.

**Screening for HIV-related neurocognitive impairment in clinical practice: Challenges and opportunities.**

*AIDS Care.* 2013 Jul 22

Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A; UK CHIC Study; UK HIV Drug Resistance Database.

**Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.**

*Antivir Ther.* 2013;18(2):213-9

Abdul-Latif M, Beckett H, Rayment M, Singh GKJ, Bower M & Nelson M.

**Shigella Flexneri enteritis in risk-taking HIV-infected MSM - a single institution experience**

*HIV Medicine* 2013, 14 (suppl 2) 76.

Jackson A, Moyle G, Watson V, Tjia J, Ammara A, Back D, Mohabeer M, Gazzard B, Boffito M

**Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.**

*J Acquir Immune Defic Syndr.* 2013;62:275-81



Samuel M, Jose S, Winston Am Nelson m, Johnson M, Chadwick D, Fisher M, Leen C, Gomples M, Gilson R, Post F, Hay P, Sabin C (UK CHIC)

**The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations**

*HIV Med* 2013 Nov 19 doi: 10.1111

Mletzko S, Rai A, Westrop S, Imami N, Shahrabi Y, Della Pria A, Howell S, Jones M, Gotch F & Bower M

**The role of interleukin-6 and Interleukin-6 receptor in multicentric Castleman's disease: Frequency of polymorphism**

*HIV Medicine* 2013, 14 (suppl 2) 26

Della Pria A, Flook M, Williams J, Goode E, Berg L, Newsom-Davis T, Nelson M & Bower M

**The spectrum of non-AIDS defining malignancy: 431 cases**

*HIV Medicine* 2013, 14 (suppl 2) 27

Chamberlain FE, Chacko L, Singh GKJ, Bower M & Nelson M

**The use of azathioprine in HIV-infected individuals**

*HIV Medicine* 2013, 14 (suppl 2) 65

Vishwanath V, Singh GKJ, Dub S, Bower M & Nelson M

**The use of dual maraviroc/ritonavir boosted darunavir combination in clinical practice**

*HIV Medicine* 2013, 14 (suppl 2) 59

Constandinou T, Vekeria S, Singh GKJ, Bower M & Nelson M

**Use of antacid preparations with HAART**

*HIV Medicine* 2013, 14 (suppl 2) 5

Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D, Cummins N, Dalmau D, Dehovitz J, Lehmann C, Sullivan A, Woolley I, Kuller L, Neaton JD, Tracy RP; INSIGHT SMART Study Team.

**HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation**

*J Am Heart Assoc* 2013; 2(4):e000264

## 2012

Waters L, Patterson B, Scourfield A, Hughes A, de Silva S, Gazzard B, Barton S, Asboe D, Pozniak A, Boffito M

**A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience**

*Int J STD AIDS*. 2012;23:546-52

Moyle GJ, Andrade-Villanueva J, Girard PM, Antinori A, Salvato P, Bogner JR, Hay P, Santos J, Astier L, Pans M, Balogh A, Biguenet S; the ReAL Study Team.

**A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.**

*Antivir Ther*. 2012. [Epub ahead of print]

Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, Tobias JK, Vanhove GF; For the NGX-4010 C119 Study Group

**A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-Associated Distal Sensory Polyneuropathy.**

*J Acquir Immune Defic Syndr*. 2012;59:126-133

Mandalia S, Westrop SJ, Beck EJ, Nelson M, Gazzard BG, Imani

**Are long-term non-progressors very slow progressors? Insights from the Chelsea & Westminster HIV cohort 1988-2010**

*PLoS One* 2012; 7 (2): e29844

Barber T, Bansi L, Leonidou L, Pozniak A, Asboe D, Nelson M, Moyle G, Boffito M, Davies N, Thornton S, Catalan J, Gazzard B

**Baseline data from the MSM Neurocog study**

*J Int AIDS Soc*. 2012 ;15:18176.

Ahmed A, Page E, Bower M & Nelson M.

**Boceprevir for the treatment of chronic hepatitis C in HIV co-infected.**

*HIV Medicine* 2012, 13 (suppl 1) 41

Scourfield A, Waters L, Martin T, Mandalia S, Bower M, Gazzard B & Nelson M.

**Can antiretrovirals increase the risk of venous thromboembolism in HIV infection?**

*HIV Medicine* 2012, 13 (suppl 1) 56.

Awoyemi D, Mandalia S, Bower M, Anderson M & Nelson M

**Can haemoglobin drop replace rapid virological response in predicting a sustained virological response?**

*HIV Medicine* 2012, 13 (suppl 1) 44.

Westrop SJ, Moyle G, Jackson A, Nelson M, Mandalia S, Imani N.

**CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.**

*Mol Med*. 2012;18:1240-8

## 2012 continued

Clutterbuck DJ, Flowers P, Barber T, Wilson H, Nelson M, Hedge B, Kapp S, Fakoya A, Sullivan AK

**Clinical Effectiveness Group of British Association for Sexual Health and HIV (BASHH) and British HIV Association (BHIVA)**

*Int J STD AIDS*. 2012 June; 23 (6): 38108

McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D, McGrath D, Farajallah A, Moyle G.

**Clinical Significance of Hyperbilirubinemia Among HIV-1-Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study.**

*AIDS Patient Care STDS*. 2012;26:259-64

Garvey L, Nelson M, Latch N, Erlwein OW, Allsop JM, Mitchell A, Kaye S, Watson V, Back D, Taylor-Robinson SD, Winston A

**CNS effects of CCR% inhibitor in HIV infected subjects: a pharmacokinetic and cerebral metabolite study**

*J Antimicrob Chemother*. 2012 Jan; 67 (1); 206-12

Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabvin C, Post FA; UK CHIC/CKD\* Study Group

**Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV positive patients**

*Nephrol Dial Transplant*. 2012 June; 27 (6): 2291-7

Westrop S, Mandalia S, Moyle G, Bower M, Nelson M & Imami

**Compounded Influence of Patient Age, ART Duration and Time since HIV-1+ Diagnosis Delineates the Immune Profile of the Ageing Cohort**

*N. CROI 2012*

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sönnnerborg A, Codoñer FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S; SEHERE collaboration in Chain

**Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.**

*Int J STD AIDS*. 2012 Aug;23(8):546-52.

Chinthapalli S, Mandalia S, Jones R, Bower M & Nelson M.

**Descriptive case series of eight HIV positive patients with foot stress fractures.**

*HIV Medicine* 2012, 13 (suppl 1) 55

Scourfield A, Zheng J, Chinthapalli S, Waters L, Martin T, Mandalia S, Nelson M

**Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals**

*AIDS*: 2012 Jul 17; 26 (22): 1399-401

Lamorde M, Byakika-Kibwika P, Tamale WS, Kiweewa F, Ryan M, Amara A, Tjia J, Back D, Khoo S, Boffito M, Kityo C, Merry C.

**Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults**

*AIDS Res Treat*. 2012;105980.

Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, Li T, Tebas P, Stevens M, Buelens A, Vanveggel S, Boven K; ECHO and THRIVE Study Groups.

**Efficacy and safety of rilpivirine in treatment naïve. HIV-1 infected patients with hepatitis B virus/hepatitis C virus coinfections enrolled in the Phase III randomised, double blind ECHO and THRIVE trials**

*J Antimicrob Chemother*. 2012 Aug; 67 (\*): 2020-8

Schipani A, Egan D, Dickinson L, Davies G, Boffito M, Youle M, Khoo SH, Back DJ, Owen A.

**Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults**

*Antivir Ther*. 2012;17:861-8

Thornton A, Rayment M, Mandalia S, Elam G, Atkins M, Jones R, Nardone A, Roberts P, Tenant-Flowers M, Anderson J, Sullivan A.

**Exploring staff attitudes to routine HIV testing in non-traditional settings: a qualitative study in four healthcare facilities.**

*Sex Transm Infect* 2012 ;88:601-6

Mletzko S, Shahrabi Y, Hislop A, Harding V, Nelson M, Gotch F & Bower M.

**Ex-vivo recognition of immediate-early T cell epitopes within open reading frame ORF50 and K8 of Kaposi's sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals**

*HIV Medicine* 2012, 13 (suppl 1) 32.

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D; on behalf of the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

**Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.**

*J Antimicrob Chemother*. 2012 Apr;67(4):995-1000

Manley J, Dunning J, Nelson M, Bower M

**HIV associated gastric natural killer? T-cell lymphoma**

*Int J STD AIDS* 2012. Jan; 23 (1): 66-7

Rayment M, Thornton A, Mandalia S, Elam G, Atkins M, Jone R, Nardone A, Roberts P, Tenant-Flowers M, Anderson J, Sullivan A.

**HIV Testing in Non-Traditional Settings - The HINTS Study: A Multi-Centre Observational Study of Feasibility and Acceptability**

*PLoS One* 2012; 7(6):e39530. Epub 2012 Jun 22

Bashford J, Atkins M, Bower M & Nelson M.

**How commonly is JC virus detected in the cerebrospinal fluid of patients with HIV?**

*HIV Medicine* 2012, 13 (suppl 1) 47

Vogel M, Page E, Boesecke C, Reiberger T, Schwarze-Zander C, Mauss S, Baumgarten A, Wasmuth JC, Nelson M, Rockstroh JK, European AIDS Treatment Network (NEAT) Study Group

**Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals**

*Clin Infect Dis.* 2012 Feb 12; 54 (4): 556-9

Vrouenraets SM, Wit FW, Garcia EF, Huber M, Brinkman K, Moyle G, Domingo P, Tarr PE, Podzamczar D, Ristola M, Gatell JM, Livrozet JM, Furrer H, Reiss P; PREPARE Study Group.

**Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue.**

*HIV Clin Trials.* 2012;13:103-10.

Beck EJ, Mandalia S, Sangha R, Youle M, Brettle R, Gompels M, Johnson M, Pozniak A, Schwenk A, Taylor S, Walsh J, Wilkins E, Williams I, Gazzard B; NPMS-HHC Steering Group

**Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.**

*PLoS One.* 2012;7(10):e47376

Salvinia Mletzko, Y Shahrabi, M Bower, K Hayward, V Harding, C Boshoff, A Benlahrech, and F Gotch.

**Modification of Dendritic Cell Function by Kaposi's Sarcoma-associated Herpesvirus Suggests a Novel Immune Evasion Strategy**

*CROI* 2012

SW Worm, M Bower, P Reiss, A Grulich,, E Fontas, F Bonnet, G Faetkenheuer, M Law, A Phillips, HJ Furrer, W El-Sadr, O Kirk, L Ryom, D Abrams, A D'Arminio Monforte, S De Wit, C Sabin, JD Lundgren on behalf of the D:A:D study group

**Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study**

*CROI* 2012

Garlassi E, Harding V, Allen H, Allin B, Lee N, Nelson M & Bower M.

**Non-melanoma skin cancers among HIV-infected persons in the HAART-era**

*HIV Medicine* 2012, 13 (suppl 1) 34

Kober C, Johnson M, Fisher M, Hill, T Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R, Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth J, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC) study

**Non-uptake of highly active antiretroviral therapy among patients with a CD4 count <350 cells ul in the UK**

*HIV Med* 2012 Jan; 13 (1); 73-8

Bradshaw D, Pallawela S, Nelson M, Scott C, Day C

**Otosyphilis: missed opportunities for early treatment**

*Sex Transm Infect.* 2012 Sept 21

Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M, Goodier MR

**PD-1 Expression on Natural Killers Cells and CD8 (+) T Cells During Chronic HIV-1 Infection**

*Viral Immunol.* 2012 Aug; 25 (4): 329-32

Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C, Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D

**Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model**

*Clin Pharmacol Ther.* 2012;92:494-502.

Jackson A, Moyle G, Dickinson L, Back D, Khoo S, Taylor J, Gedela K, Abongomera G, Gazzard B, Boffito M.

**Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.**

*Antivir Ther.* 2012;17:19-24.

## 2012 continued

Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C; Swiss HIV Cohort Study Group

**Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.**

*Antimicrob Agents Chemother.* 2012;56:2959-66.

Tan J, Sonali S, Bower M, Smith B & Nelson M

**Reasons for non-utilisation of a home delivery service among patients stabilised on antiretroviral therapy at 3 outpatient clinic sites**

*HIV Medicine* 2012, 13 (suppl 1) 19.

Fakoya I, Johnson AM, Fenton K, Anderson J, Nwokolo N, Sullivan AK, Munday P, Burns FM

**Religion and HIV diagnosis among Africans living in London**

*HIV Med* 2012; 13:617-22

Myers J, Rayment M, Sonecha S, Moyle G, Boffito M.

**Room for manoeuvre when prescribing statins to dyslipidaemic patients on antiretroviral therapy.**

*HIV Med.* 2012;13(3):190-2.

Kumar N, Bower M, Nelson M

**Severe vitamin D deficiency in a patient treated for hepatitis B with tenofovir**

*Int J STD AIDS* 2012. Jan; 23 (1): 59-60

Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoo S, Davies G

**Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies**

*J Acquir Immune Defic Syndr.* 2012;62:60-6

Lamorde M, Byakika-Kibwika P, Boffito M, Nabukeera L, Mayito J, Ogwal-Okeng J, Tjia J, Back D, Khoo S, Ryan M, Merry C

**Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults**

*J Acquir Immune Defic Syndr.* 2012;60:295-8

Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N.

**The Effect of a 12-Week Course of Omega-3 Polyunsaturated Fatty Acids on Lipid Parameters in Hypertriglyceridemic Adult HIV-infected Patients Undergoing HAART: A Randomized, Placebo-Controlled Pilot Trial.**

*Clin Ther.* 2012;34:67-76

Carr A, Hoy J, Pozniak A.

**The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?**

*PLoS Med.* 2012;9(7):e1001240.

Thomas Newsom-Davis, Paul Fox, Victoria Bradley, Alessia Dalla Pria, Mark Nelson, Mark Bower

**The features and outcome of HIV-associated anal cancer in screened and unscreened populations**

*J Clin Oncol* 30, 2012 (suppl; abstr e14574

Shavadia J, Shah R, Yonga G, Patel R, Stebbing J, Nelson M

**The influence of antiretroviral therapy on QTc interval in an African cohort**

*Clin Infect Dis.* 2012 Feb 1; 54 (3): 448-9

Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff

**The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors for patients with viral load <50 HIV-1 RNA copies/ML at baseline.**

*HIV Med.* 2012 Aug; 13 (7): 398-405

UK Collaborative Group on HIV Drug Resistance, Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown AL, Churchill D, Williams I, Geretti AM, Phillips A, Mackie N, Murphy G, Castro H, Pillay D, Cane P, Dunn D, Dolling D.

**Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study**

*BMJ.* 2012 Aug 21;345:e5253

S. Kassam, M. Bower, S.M. Lee, J. De Vos, P. Fields, S. Gandhi, M. Nelson, S. Montoto, M. Tenant-Flowers, F. Burns, R. Marcus, S.G. Edwards, K. Cwynarski,

**Treatment intensification for HIV-positive patients with high-risk diffuse large B-cell lymphoma does not improve outcome: a retrospective, multi-centre study**

*EHA* 2012

Clutterbuck D, Flowers P, Barber T, Wilson H, Nelson M, Hedge B, Kapp S, Fakoya A, Sullivan AK

**UK national guideline on safer sex advice**

*International Journal of STD & AIDS* 2012; 23

Caseiro MM, Nelson M, Diaz RS, Gathe J, de Andrade Neto JL, Slim J, Solano A, Netto EM, Mak C, Shen J, Greaves W, Dunkle LM, Vichez RA, Zeinecker J

**Vicriviroc plus optimised background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomised phase III trials**

*J Infect.* 2012 OCT; 65 (4): 326-35 2012

2011

V Tittle, C Fernandez, A Scourfield, B Gazzard, M Bower and M Nelson.

**A comparison of inpatient admissions in 2005 and 2010 at a tertiary centre**

*HIV Medicine* 2011, 12 (Suppl 1), 68.

S Westrop, G D'Souza, M Bower, B Gazzard, M Nelson and N Imami

**Algorithmic prediction for the identification of novel HLA-B\*2705-restricted HIV-1 CD8 T-cell epitopes: assessment of epitope stability, affinity and specific T-cell profile**

*HIV Medicine* 2011, 12 (Suppl 1), 29.

A Scourfield, A Jackson, L Waters, J Dunning, S de Silva, N Francis, P Holmes, M Nelson and M Bower.

**An atypical presentation of Kaposi's sarcoma.**

*HIV Medicine* 2011, 12 (Suppl 1), 39.

D Awoyemi, B Gazzard, M Bower, S Yau and M Nelson

**Antiretroviral drug dosing in renal impairment**

*HIV Medicine* 2011, 12 (Suppl 1), 54

A Scourfield, L Waters, V Tittle, T Martin, N Rockwood, B Gazzard, M Bower and M Nelson

**Azathioprine use as a novel treatment for cryptococcal immune reconstitution and inflammatory syndrome in HIV**

*HIV Medicine* 2011, 12 (Suppl 1), 45.

Byakika-Kibwika P, Lamorde M, Lwabi P, Nyakoojo WB, Okaba-Kayom V, Mayanja-Kizza H, Boffito M, Katabira E, Back D, Khoo S, Merry C

**Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults**

*Chemother Res Pract.* 2011;393976

M Alfa-Wali, T Allen-Mersh, A Antoniou, D Tait, T Newsom-Davis, B Gazzard, M Nelson and M Bower

**Chemoradiotherapy of anal cancer in HIV patients causes prolonged CD4 cell count suppression.**

*HIV Medicine* 2011, 12 (Suppl 1), 7. 2011

S. Merchant, B. Lee, M. Nelson, T. Newsom-Davis, K. Naresh, B. Gazzard, M. Bower

**Clinical features and outcome in 61 patients with HIV-associated multicentric Castleman's disease.**

*6th IAS Conference on HI pathogenesis, treatment and prevention (Rome) 2011.*

J Krell, T Newsom-Davis, M Bower, J Stebbing and M Nelson

**Coinfection with hepatitis B virus does not increase the risk of HIV-associated non-Hodgkin lymphoma**

*HIV Medicine* 2011, 12 (Suppl 1), 37.

S Merchant, V Bradley, M Mak, B Gazzard, M Nelson, M Bower and T Newsom-Davis

**Demographics, histology and survival in HIV-associated lung cancer**

*HIV Medicine* 2011, 12 (Suppl 1), 37

Mounier N, Bower M, Spina M, Besson C, Schiantarelli C, Re A, Bonnet F, Hentrich M, Schommers P, Van Den Neste E, Costagliola D, Borsatti E and Tirelli U.

**Early determination of treatment sensitivity in HIV-related Hodgkin lymphoma by FDG-PET/CT after two cycles of ABVD chemotherapy**

*GECAT (European Cooperative Study Group on AIDS and Tumors). Third international workshop on interim-PET in lymphoma, Menton, France 2011*

S Merchant, A Marouf, V Bradley, J Myers, T Newsom-Davis, M Nelson, B Gazzard and M Bower.

**Effect of raltegravir on rates of chemotherapy-induced neutropenia in HIV lymphomas**

*HIV Medicine* 2011, 12 (Suppl 1), 36.

R Robey, S Mletzko, M Bower, R Meys, M Boffito, M Nelson, S Merchant, B Gazzard, C Boshoff and F Gotch

**Ex-vivo recognition of late-lytic CD8 epitopes specific for Kaposi's sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals**

*HIV Medicine* 2011, 12 (Suppl 1), 23.

Merchant S, Marouf A, Hachach-Haram N, Nelson M, Bower M and Newsom-Davis T

**Histopathological trends in HIV-associated lung cancer**

*Lung Cancer* 2011; 71(S1), 11



2011 continued

S Montoto, K Shaw, J Okosun, S Gandhi, P Fields, A Wilson, M Shanyinde, K Cwynarski, R Marcus, J de Vos, AM Young, M Tenant-Flowers, C Orkin, M Johnson, D Chilton, J Gribben, M Bow

**HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era**

*Proc American Society of Haematology 2011.*

Michael Furman, Pascual Balsalobre, Brady E. Beltran, Michele Bibas, Mark Bower, Weina Chen, Silvia Montoto, Roberto N. Miranda, Nahid M. Nanaji, Jose-Tomas Navarro, Adam C. Seegmiller, Julie M. Vose and Jorge J Castill

**HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study**

*Proc American Society of Haematology 2011.*

E Page, M Bower, D Kaplan, J Daruich, L Kikuchi, M Marques Molero, D Rimland, M Goetz, J Pineda, K Marks, N Brau and M Nelson

**HIV-infected patients with hepatocellular carcinoma live longer if they have undetectable HIV RNA.**

*HIV Medicine 2011, 12 (Suppl 1), 7. 2011*

K Shahabuddin, R Mehta, S Graeme-Baker, H Gay, C Davies, N Khan, F Kazmi, B Gazzard, M Bower and M Nelson.

**Imaging of anorectal pathology by MR in people with HIV infection**

*HIV Medicine 2011, 12 (Suppl 1), 38*

S Mletzko, A Kyriakou, R Robey, M Bower, M Nelson, S Merchant, B Gazzard, C Boshoff and F Gotch

**Impaired dendritic cell (DC) function in Kaposi's sarcoma-associated herpesvirus (KSHV) infections.**

*HIV Medicine 2011, 12 (Suppl 1), 28.*

S Westrop, D Lagos, M Bower, F Gotch, B Gazzard, C Boshoff and N Imami

**Increased incidence of multicentric Castleman's disease in KSHV+ HIV-1+ individuals of Black African ethnicity may result from the higher frequency of the TLR4 single nucleotide polymorphism A299G.**

*HIV Medicine 2011, 12 (Suppl 1), 6.*

Okusun J, Warbey V, Shaw K, Montoto S, Fields P, Marcus R, Virchis A, McNamara C, Bower M & Cwynarski K. Haematologica

**Interim FDG-PET predicts response and progression free survival in patients with Hodgkin lymphoma and HIV infection**

*Proc European Haematology Association. 2001 A774.*

Bulteel N, Bower M, Gazzard B, Mandalia S, Nelson M

**Is emtricitabine associated with reduced levels of the M184V mutation when compared with lamivudine?**

*13th European AIDS Conference, Belgrade 2011*

L Baber, S Sonecha, S Mandalia, M Bower, B Gazzard and M Nelson

**Patients' willingness to switch from a single-tablet regimen (STR) to individual drugs as part of a potential cost-saving strategy**

*HIV Medicine 2011, 12 (Suppl 1), 80.*

Letang E, Lewis J, Bower M, Mosam A, Borok M, Naniche D, Newsom-Davis T, Shaik F, Campbell T and Easterbrook P.

**Predictors of paradoxical IRIS associated with Kaposi's sarcoma in Sub-Saharan Africa and the UK: Developing a predictive score**

*18th conference on retroviruses and opportunistic infections (CROI) 2011, 417.*

Beck EJ, Mandalia S, Sangha R, Sharott P, Youle M, Baily G, Brettle R, Gompels M, Johnson M, McCarron B, Ong E, Pozniak A, Schwenk A, Taylor S, Walsh J, Wilkins E, Williams I, Gazzard B; NPMS-HHC Steering Group.

**The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008.**

*PLoS One. 2011;6(12)*

B Lee, S Merchant, A Sita-Lumsden, B Gazzard, M Nelson and M Bower

**The incidence and correlates of paraneoplastic syndromes in 62 HIV-positive patients with Hodgkin's Lymphoma.**

*HIV Medicine 2011, 12 (Suppl 1), 37.*

K. Wheatley, J. Roe, M. Nelson, T. Newsom-Davis, B. Gazzard, M. Bower.

**The safety of Rituximab in HIV non-Hodgkin lymphoma patients with low CD4 cell counts**

*6th IAS Conference on HI pathogenesis, treatment and prevention (Rome) 2011.*

J Roe, K Wheatley, T Kordbacheh, T Newsom-Davis, B Gazzard, M Nelson and M Bower.

**The safety of rituximab in patients with low CD4 cell counts**

*HIV Medicine 2011, 12 (Suppl 1), 36.*

A Scourfield, T Martin, N Rockwood, L Waters, S de Silva, P Holmes, M Bower, B Gazzard and M Nelson.

**The use of faecal elastase to screen for pancreatic insufficiency in HIV-infected individuals**

*HIV Medicine 2011, 12 (Suppl 1), 53*

A Scourfield, L Waters, T Martin, N Rockwood, M Bower, M Nelson and B Gazzard.

**Will earlier diagnosis of HIV reduce the presentation of serious opportunistic infections?**

*HIV Medicine* 2011, 12 (Suppl 1), 62.

2010

Moyle G, Boffito M, Stoehr A, Rieger A, Shen Z, Manhard K, Sheedy B, Hingorani V, Raney A, Nguyen M, Nguyen T, Ong V, Yeh LT, Quart B.

**A Phase 2a randomized controlled trial of the short term activity, safety and pharmacokinetics of a novel NNRTI, RDEA806 in HIV-1 positive, antiretroviral-naive subjects.**

*Antimicrob Agents Chemother.* 2010 May 24.

Teague A, Scott C, Bower M, Gazzard B, Nelson M, Stebbing J.

**A single-center cohort experience of raltegravir in salvage patients failing therapy.**

*J Acquir Immune Defic Syndr.* 2010 Apr;53(5):666-7

Gazzard B, Balkin A, Hill A.

**Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.**

*AIDS Rev.* 2010 Apr-Jun;12(2):67-75.

Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, Fisher M, Gilleece Y, Gilson R, Freedman A, Kulasegaram R, Agarwal K, Sabin C, Deacon-Adams C; BHIVA Viral Hepatitis Working Group

**British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010**

*HIV Med.* 2010 Jan;11(1):1-30

Cooper V, Moyle G, Fisher M, Reilly G, JEwan J, Liu H.C, Horne R for the SWEET group UK

**Changes in adherence and patients' perceptions of treatment in a 48 week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.**

*AIDS Care* 2010: in press

Page EE, Cox A, Atkins M, Nelson MR.

**Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells**

*AIDS.* 2010 Jun 1;24(9):1267-71

Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns B, Pillay D, Nelson M.

**Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.**

*Antiviral Res.* 2010 May;86(2):224-6

Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M, Gazzard B, Gilson R, Johnson M, Leen C, Orkin C, Schwenk A, Walsh J, Winston A, Babiker A, Delpech V; on behalf of the UK Collaborative HIV Cohort (UK CHIC) Study Group.

**Data linkage reduces loss to follow-up in an observational HIV cohort study.**

*J Clin Epidemiol.* 2010 Mar 26.

Moyle G, Demasi R, Hill A.

**Does earlier HIV RNA suppression provide long-term benefits?**

*AIDS* 2010;24:1591-3

Falutz J, Mamputu J-C, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.

**Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal**

*J Clin Endocrinol Metab* 16 June 2010,

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.

**Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension.**

*J Acquir Immune Defic Syndr.* 2010;53:311-22

Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group.

**Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.**

*AIDS.* 2010 Jan 2;24(1):55-65.

On I, Beardsell H, Smith B, Mandalia S, Bower M, Gazzard B, Nelson M, Stebbing J.

**Epidemiology of herpes simplex virus types 2 and 1 amongst men who have sex with men (MSM) attending sexual health clinics in England and Wales: implications for HIV prevention and management**

*Eurosurveillance* in press.



## 2010 continued

R Jones, A Menon-Johansson, AM Waters, AK Sullivan

**eTriage - a novel, web-based triage and booking service: enabling timely access to sexual health clinics**

*Int J STD & AIDS* 2010; 21:30-33.

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara C, Orkin C, Nelson M, Johnson M, Bower M, Cwynarski AK.

**Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.**

*AIDS*. 2010 Mar 27;24(6):851-6

Ridha E, Cookson H, Devitt E, Nelson M.

**Febrile neutropenia in a HIV positive individual post-chemotherapy**

*J Clin Virol*. 2010 May;48(1):2-5. Epub 2010 Feb 18

Alfa-Wali A, Antoniou A, Allen-Mersh T, Tekkis P, Tate D, Sita Lumsden A, Nelson M & Bower M

**HIV-associated colorectal cancer and the immunological effects of treatment**

*HIV Medicine* 2010, 11 (suppl 1), 58.

Wilson J, Devitt E, Rampling T, Namulema E, Bower M & Nelson M

**Increasing prevalence of pulmonary tuberculosis in HIV-infected individuals in Kampala, Uganda.**

*HIV Medicine* 2010, 11 (suppl 1),

Menon-Johansson A.S, Cohen C.E., Jones R., Nwokolo N., McOwan A., Barton S.E. & Sullivan A.K

**Interventions to increase access to STI services: A study of England's 'High Impact Changes' across three central London clinics**

*STI* 2010 in press

Yilmaz S, Boffito M, Collot-Teixeira S, De Lorenzo F, Waters L, Fletcher C, Back D, Pozniak A, Gazzard B, McGregor JL.

**Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.**

*Genomics*. 2010 Jul;96(1):57-65. Epub 2010 Mar 28. 2010

UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group

**Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy**

*Clin Infect Dis*. 2010 May 1;50(9):1275-85.

Revell AD, Wang D, Harrigan R, Hamers RL, Wensing AM, Dewolf F, Nelson M, Geretti AM, Larder BA

**Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings**

*J Antimicrob Chemother*. 2010 Apr;65(4):605-7

McClellan H, CA Carne, AK Sullivan, A Menon-Johansson, R Gokhale, G Sethi, AG Mammen-Tobin, D Daniels.

**National Audit of Asymptomatic Screening in UK Genitourinary Medicine Clinics: Clinic Policies Audit.**

*Int J STD & AIDS* in press

Rashid T, Meryon I, Mandalia S, Waters L, Devitt E, Bower M, Jones R & Nelson M

**No association of vitamin D levels with individual antiretroviral agents, duration of HIV infection, alkaline phosphatase levels or bone mineral density findings**

*HIV Medicine* 2010, 11 (suppl 1), 34

Bower M, Montoto S, Cwynarski K, Sita Lumsden A, Rajab R, Okosum J, Orkin C, Nelson M, Isaacson P, Calaminici M & Naresh K

**Non-germinal centre subtype of AIDS-related diffuse large B-cell lymphomas associated with improved survival.**

*HIV Medicine* 2010, 11 (suppl 1), 13.

Kityo C, Walker AS, Dickinson L, Lutwama F, Kayiwa J, Ssali F, Nalumenya R, Tumukunde D, Munderi P, Reid A, Gilks CF, Gibb DM, Khoo S; DART Trial Team

**Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.**

*Antimicrob Agents Chemother*. 2010 Jul;54(7):2965-73.

Price H, Asboe D, Gazzard B, Fearnhill E, Pillay D, Dunn D: UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study

**Positive and negative drug selection pressures on the N3481 connection domain mutation: new insights from in vivo data**

*Anitfir Ther*. 2010; 15(2): 203-11.

Willis J, Jones R, Nwokolo N and Levy J

**Protein and Creatine Supplements and Misdiagnosis of Kidney Disease**

*BMJ* 2010;340:b5027

Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczar D, Fisher M, Norden AG, Cavassini M, Rieger A, Khuong-Josses MA, Branco T, Pearce HC, Givens N, Vavro C, Lim ML.

**Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT Study**

*J Acquir Immune Defic Syndr.* 2010 Apr 24.

Jones R, Brown D, Nelson M, Low E, Bhagani S, Atkins M, Danta M, Dusheiko G, Pybus O, Asboe D.

**Re-emergent hepatitis C viremia after apparent clearance in HIV-positive men who have sex with men: reinfection or late recurrence?**

*J Acquir Immune Defic Syndr.* 2010 Apr 1;53(4):547-50. No abstract available. Erratum in: *J Acquir Immune Defic Syndr.* 2010 May 1;54(1):112

Williams J, Jones R, Nelson M, Barlow S, Short D, Savage P, Seckl M, Schmidt P & Bower M.

**Six cases of gestational trophoblastic tumours in women living with HIV.**

*HIV Medicine* 2010, 11 (suppl 1), 60.

Scourfield A, Waters L, Brown G, Bower M & Nelson M.

**Spectrum of neurological disease in patients with discordant HIV-1 RNA levels in plasma and cerebrospinal fluid.**

*HIV Medicine* 2010, 11 (suppl 1), 34-5.

HIV-CAUSAL Collaboration

**The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals**

*AIDS.* 2010 Jan 2;24(1):123-37

Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ.

**The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers**

*Antivir Ther.* 2010;15:227-33.

on I, Beardsell H, Smith B, Mandalia S, Bower M, Gazzard B, Nelson M, Stebbing J.

**The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.**

*Antiviral Res.* 2010 May;86(2):227-9

Dunn D, von Wyl V, Price H, Asboe D.

**The impact of the 0-0 cell on measures of amino acid covariation**

*AIDS.* 2010 Jan 2;24(1):159-60. No abstract available

Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C.

**The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml**

*AIDS.* 2010 Jan 16;24(2):223-30

Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet M, Valantin MA, Katlama C, Rockstroh JK, Nelson M.

**Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort**

*Antivir Ther.* 2010;15(2):267-79

Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M, Porter K, Anderson J, Gompels M, Leen C, Ainsworth J, Orkin C, Nelson M, Rice B, Phillips A; UK Collaborative HIV Cohort (CHIC) Study and the Health Protection Agency

**Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations**

*HIV Med.* 2010 Aug;11(7):432-8

Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, Rajacic N, Goodrich J.

**Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2.**

*J Acquir Immune Defic Syndr.* 2010 Aug 11

Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D

**Unselected hepatitis C screening of men who have sex with men attending sexual health clinics**

*J Infect.* 2010 May;60(5):351-3. Epub 2010 Feb 12. PMID: 20153770

Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C, Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E, Dally L, Gotch F, Walker B, Gilmour J, Hayes P

**Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.**

*J Infect Dis.* 2010 Mar;201(5):720-9 2010

Brown G, Scott C, Teague A, Bower M, Gazzard B & Nelson M

**Virological efficacy of darunavir/ritonavir monotherapy in clinical practice**

*HIV Medicine* 2010, 11 (suppl 1), 24

2009

Stebbing J, Farouk L, Panos G, Anderson M, Jiao LR, Mandalia S, Bower M, Gazzard B, Nelson M

**A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis**

*J Clin Gastroenterol.* 2009 Sep 9.

Stebbing J, Scourfield A, Koh G, Taylor C, Taylor S, Wilkins E, Gazzard B, Nelson M, Jones R.

**A multicentre cohort experience with double-boosted protease inhibitors.**

*J Antimicrob Chemother.* 2009 Aug;64(2):434-5.

Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H, Ebrahimi R, Reilly G for the SWEET (Simplification With Easier Emtricitabine Tenofovir) group UK

**A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals**

*Journal of Acquired Immune Deficiency Syndromes.* 2009;51:562-568

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN

**Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.**

*J Infect Dis.* 2009 Sep 15;200(6):973-83.

Holmes P, Low E, Bower M, Anderson M & Nelson M.

**Acute hepatitis C is not associated with abnormal fibroscan readings**

*HIV Medicine* 2009, 10 (Suppl1), 30

Ng SC, Gazzard B.

**Advances in sexually transmitted infections of the gastrointestinal tract**

*Nat Rev Gastroenterol Hepatol.* 2009 Aug 25

Powles S, Weir J, Francis N, Newsom-Davis T, Crook T, Boffito M, Nelson M & Bower M.

**AIDS Kaposi's sarcoma: outcomes in 254 consecutive patients diagnosed in modern times**

*HIV Medicine* 2009, 10 (Suppl1), 10.

Walmsley S, Wilkin T, Moyle G

**Antiretroviral rounds. Too many options?**

*AIDS Clin Care.* 2009;21:13-5.

Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax P

**Antiretroviral therapy update from the 48th ICAAC/46th IDSA annual meeting**

*AIDS Read.* 2009;19:22-31.

Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF, Moyle GJ, Jackson AA, Gazzard BG.

**Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.**

*Br J Nutr.* 2009 Jun 1:1-9.

Woodcock H, Holmes P, Powles S, Dunning J, Bower M & Nelson M.

**Burkitt's non-Hodgkin lymphoma presenting as an isolated Bell's palsy in HIV-positive patients**

*HIV Medicine* 2009, 10 (Suppl1), 232009

Scott C, Azwa A, Cohen C, McIntyre M, Desmond N

**Catscratch disease: a diagnostic conundrum**

*Int J STD AIDS.* 2009 Aug; 20(8) 585-6

Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A.

**Causes and consequences of incomplete HIV RNA suppression in clinical trials.**

*HIV Clin Trials.* 2009 Sep-Oct;10(5):289-98.

Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips AN, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B, Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels M, Sabin CA

**CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.**

*Haematologica.* 2009 Jun;94(6):875-80

Teague A, Scott C, Bower M, Gazzard B & Nelson M.

**Clinical experience of raltegravir in salvage patients failing therapy, 48-week data**

*HIV Medicine* 2009, 10 (Suppl1), 17

Moyle G, Rajicic N, Goodrich J, Mayer H, Valdez H.

**Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials**

*AIDS* 2009: 23:1613.

Panos G, Farouk L, Stebbing J, Holmes P, Valero S, Randell P, Bower M, Gazzard B, Anderson M, Nelson M

**Cryptogenic pseudocirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIV**

*J Acquir Immune Defic Syndr.* 2009 Dec 1;52(4):525-7

Bower M, Veraitch O, Szydlo R, Charles P, Kelleher P, Gazzard B, Nelson M, Stebbing J.

**Cytokine changes during rituximab therapy in HIV-associated multicentric Castlemans disease.**

*Blood.* 2009 May 7;113(19):4521-4.

Scott C, Teague A, Bower M, Gazzard B & Nelson M

**Darunavir/ritonavir once daily: a single-centre cohort experience**

*HIV Medicine* 2009, 10 (Suppl1), 8

Soodalter J, Sousa M, Boffito M

**Drug-drug interactions involving new antiretroviral drugs and drug classes.**

*Curr Opin Infect Dis.* 2009 Feb;22(1):18-27.

Scourfield A, Waters L, Randell PA, McCormick K, Armenis K, Bower M & Nelson M

**Effect of raltegravir on ALT in subjects coinfecting with HIV and hepatitis C**

*HIV Medicine* 2009, 10 (Suppl1), 31

Arastéh K, Yeni P, Pozniak A, Grinsztejn B, Jayaweera D, Roberts A, Hoy J, De Meyer S, Vangeneugden T, Tomaka F.

**Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.**

*Antivir Ther.* 2009;14(6):859-64.

Pozniak A, Müller L, Salgo M, Jones JK, Larson P, Tweats D.

**Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview.**

*AIDS Res Ther.* 2009 Aug 6;6:18.

Gregson JN, Steel A, Bower M, Gazzard BG, Gotch FM & Goodier MR.

**Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1 infected individuals.**

*AIDS* 2009, 23: 29-34.

Wilson J, Montoto S, Shaw K, Orkin C, Johnson M, Nelson M, Bower M & Cwynarski K.

**Excellent immunological recovery following the intensive chemotherapy CODOX-M IVAC, an effective therapy for HIV associated Burkitt's lymphoma.**

*HIV Medicine* 2009, 10 (Suppl1), 5

Dunning J, Myers J, Holmes P, Stuart-Buttle C, Bower M & Nelson M.

**Experience with ritonavir/atazanavir in HIV-positive antiretroviral naive individuals commencing therapy.**

*HIV Medicine* 2009, 10 (Suppl1), 18

Hill A, Sawyer W, Gazzard B.

**Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data**

*HIV Clin Trials.* 2009 Jan-Feb;10(1):1-12.

Barker R, Kazmi F, Stebbing J, Ngan S, Chinn R, Nelson M, O'Doherty M & Bower M.

**FDG-PET/CT imaging in the management of HIV-associated multicentric Castlemans disease**

*Eur J Nucl Med Imaging.* 2009, 36: 648-52

Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V, Bower M, Dezube BJ

**Gastroenteropancreatic Neuroendocrine Tumors in Patients With HIV Infection: A Trans-Atlantic Series.**

*Am J Med Sci.* 2009 Jan;337(1):1-4.

Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Moller H & Bower M

**Highly active antiretroviral therapy and the incidence of Non-AIDS defining cancers in people with HIV infection**

*J Clin Oncol.* 2009 Feb 20;27(6):884-90.

Price H, Sullivan AK

**HIV opt out increases the offer and uptake of HIV tests in a GUM clinic**

*Int J STD AIDS.* 2009 Jan;20(1):56-7.

Gazzard B.

**HIV testing in the UK**

*Lancet.* 2009 Aug 1;374(9687):377

Vogel M, Nelson M.

**HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?**

*Eur J Med Res.* 2009 Nov 24;14 Suppl 3:36-42. Review.

## 2009 continued

Herasimtschuk A, Nelson M, Moyle G, Bower M & Imani N  
**Impact of recombinant human growth hormone on T-cell phenotype and function in vitro and in vivo during treated HIV-1 infection.**

*HIV Medicine* 2009; 10 (Suppl1), 5.

Benn P, Sauret-Jackson V, Cartledge J, Ruff C, Sabin CA, Moyle G, Linney A, Reilly G, Edwards S.

**Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors**

*HIV Medicine* 2009;10:351-5

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

**Interruption of antiretroviral therapy is associated with increased plasma cystatin C**

*AIDS*. 2009 Jan 2;23(1):71-82.

Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C; on behalf of the UK Collaborative HIV Cohort (CHIC) Study

**Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations?**

*A New Definition Derived From a Large Cohort Study.*

Crook T, Syed N, Papoudou-Bai A, Stebbing J, Naresh K, Nelson M, Hatzimichael E & Bower M

**Methylation reversal in high grade B-cell lymphoma cell lines identifies novel epigenetic changes conserved between immunocompetent and HIV-positive hosts and others specific to HIV-associated lymphomas.**

*HIV Medicine* 2009, 10 (Suppl1), 4.

Buisson S, Benlahrech A, Gazzard B, Gotch F, Kelleher P, Patterson S.

**Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10.**

*J Infect Dis*. 2009 Jun 15;199(12):1862-71.

Dunning J, Nelson M.

**Novel strategies to treat antiretroviral-naive HIV-infected patients.**

*J Antimicrob Chemother*. 2009 Oct;64(4):674-9.

Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L

**Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.**

*AIDS*. 2009 Aug 24;23(13):1679-88.

Sekar V, Lefebvre E, Mariën K, De Pauw M, Vangeneugden T, Pozniak A, Hoetelmans RM.

**Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.**

*Br J Clin Pharmacol*. 2009 Jul;68(1):116-9.

Boffito M, Jackson A, Lamorde M, Back D, Watson V, Taylor J, Waters L, Asboe D, Gazzard B, Pozniak A.

**Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers.**

*J Acquir Immune Defic Syndr*. 2009 Jul 17

Coyne KM, Pozniak AL, Lamorde M, Boffito M

**Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents**

*AIDS*. 2009 Feb 20;23(4):437-46.

Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G, Khoo S, Pozniak A, Aarons L.

**Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.**

*J Antimicrob Chemother*. 2009 Jun;63(6):1233-43. *Pub* 2009 Mar 28

Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, Klein CE, Chiu YL, King MS, Bernstein BM.

**Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.**

*AIDS Res Hum Retroviruses*. 2009 Mar;25(3):269-75.

De Lorenzo F, Boffito M, Collot-Teixeira S, Gazzard B, McGregor JL, Shotliff K, Xiao H.

**Prevention of atherosclerosis in patients living with HIV.**

*Vasc Health Risk Manag*. 2009;5(1):287-300.

Moyle G, Dejesus E, Boffito M, Wong RS, Gibney C, Badel K, Macfarland R, Calandra G, Bridger G, Becker S; X4 Antagonist Concept Trial Study Team.

**Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1.**

*Clin Infect Dis*. 2009;48:798-805.



Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST; OPTIMA Team1.

**Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.**

*J Acquir Immune Defic Syndr.* 2009 Aug 15;51(5):631-9.

Annan NT, Sullivan AK, Nori A, Naydenova P, Alexander S, McKenna A, Azadian B, Mandalia S, Rossi M, Ward H, Nwokolo N.

**Rectal Chlamydia - a reservoir of undiagnosed infection in men who have sex with men.**

*Sex Transm Infect* 2009; 85:176-9.

Tan LK, Gilleece Y, Mandalia S, Murungi A, Grover D, Fisher M, Atkins M, Nelson M.

**Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir**

*J Viral Hepat.* 2009 Jul;16(7):471-8.

Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration.

**Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.**

*AIDS.* 2009 Aug 24;23(13):1689-99

Boyle BA, Cohen CJ, DeJesus E, Elion R, Frank I, Moyle GJ, Sax PE

**Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use**

*AIDS Read.* 2009;19:158-60.

Coyne KM, Banks A, Heggie C, Scott CJ, Grover D, Evans C, Mandalia S, McLean KA, Cohen CE

**Sexual health of adults working in pornographic films**

*Int J STD AIDS.* 2009 Jul;20(7):508-9

Barton S

**Sexually transmitted diseases by Dr Lisa Marr**

*AIDS Care.* Vol 21. No. 4 April 2009

Arastéh K, Rieger A, Yeni P, Pozniak A, Boogaerts G, van Heeswijk R, de Béthune MP, Peeters M, Woodfall B.

**Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.**

*Antivir Ther.* 2009;14(5):713-22.

Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, Lou Y, Yuen GJ, Min SS, Guerini EM.

**Steady state pharmacokinetics of plasma abacavir and intracellular carbovir triphosphate following abacavir 600mg once daily and 300g twice daily in HIV-infected subjects**

*Antimicrob Agents Chemother.* 2009;53:1532-8

Moyle G, Boffito M, Fletcher C, Higgs C, Hay PE, Song IH, Lou Y, Yuen GJ, Min SS, Guerini EM

**Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.**

*Antimicrob Agents Chemother.* 2009 Apr;53(4):1532-8

Furco A, Gosrani B, Nicholas S, Williams A, Braithwaite W, Pozniak A, Taylor G, Asboe D, Lyall H, Shaw A, Kapembwa M

**Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance**

*AIDS.* 2009 Jan 28;23(3):434-5. No abstract available

Teague A, Scott C, Youngstein T, Bower M, Gazzard B & Nelson M.

**Switching to raltegravir: a successful strategy in treatment-experienced patients with toxicity? 48 week data**

*HIV Medicine* 2009, 10 (Suppl1), 21.

Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study.

**The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.**

*HIV Med.* 2009 Jan;10(1):35-43. Epub 2008 Nov 10.

Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, Boffito M, Gazzard B, Nelson M

**The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.**

*AIDS.* 2009, 23(13):1701-6.

Coyne K, Mandalia S, McCullough S, Catalan J, Noestlinger C, Colebunders R, Asboe D

**The International Index of Erectile Function: development of an adapted tool for use in HIV-positive men who have sex with men.**

*J Sex Med.* 2010 Feb;7(2 Pt 1):769-74. Epub 2009 Nov 12

## 2009 continued

Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J.

**The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active Antiretroviral Therapy in Antiretroviral-Naive Individuals**

*J Acquir Immune Defic Syndr.* 2009 Jun 1;51(2):140-6.

Stebbing J, Wong N, Tan L, Scourfield A, Jiao L, Shousha S, Grover D, Bower M, Nelson M

**The relationship between prolonged antiretroviral therapy and cryptogenic liver disease**

*J Acquir Immune Defic Syndr.* 2009 Apr 1;50(5):554-6.

Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M.

**The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease.**

*Ann Oncol.* 2009, 20:775-9.

Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M, Gazzard B & Stebbing J.

**Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era.**

*J Acquir Immune Defic Syndr.* 2009, 50: 113-114.

Westrop SJ, Qazi NA, Pido-Lopez J, Nelson MR, Gazzard B, Gotch FM, Imami N.

**Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers.**

*PLoS One.* 2009;4(5):e5474

Vogel M, Page E, Nelson M, Rockstroh JK.

**Treatment of acute hepatitis C in HIV-positive individuals: what are the challenges?**

*J HIV Ther.* 2009 Mar;14(1):8-12. Review

A. Hughes, E. Jungmann, S. Manney, L. Muromba, N. Nwokolo, N. Panahmand, S.T. Sadiq, M. Slinn, R. Stack, A.K. Sullivan.

**United Kingdom acquisition of HIV infection in African residents in London: more than previously thought.**

*AIDS* 2009; 23:262-6.

Stebbing J, Asghar AK, Holmes P, Bower M, Isenman HL & Nelson M. J

**Use of ezetimibe during HIV infection**

*Antimicrob Chemother.* 2009, 6: 43-52.

Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK Collaborative HIV Cohort Study.

**Virological response to initial antiretroviral regimens containing abacavir or tenofovir.**

*J Infect Dis.* 2009 Sep 1;200(5):710-4.

## 2008

Gabriel I, Apperley J, Bower M, Chaidos A, Gazzard B, Giles C, Kew A, Nelson M, Kanfer E.

**A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease**

*AIDS.* 2008 Feb 19;22(4):539-40

Pozniak AL, Boffito M, Russell D, Ridgway CE, Muirhead GJ.

**A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.**

*Br J Clin Pharmacol.* 2008 Apr;65 Suppl 1:54-9

Boffito M, Abel S.

**A review of the clinical pharmacology of maraviroc. Introduction**

*Br J Clin Pharmacol.* 2008 Apr;65 Suppl 1:1-4

Scott C, Jogiya R, Teague A, Bower M, Gazzard B & Nelson M

**A single centre experience with darunavir/ritonavir (DRV/r) (600mg/100mg) and optimised background regimen in clinical practice**

*HIV Medicine* 2008, 9 (Suppl 1): 14 2008

Scott C, Staughton RC, Bunker CJ, Asboe D

**Acne vulgaris and acne rosacea as part of immune reconstitution disease in HIV-1 infected patients starting antiretroviral therapy.**

*Int J STD AIDS.* 2008 Jul;19(7):493-5

FM Burns, R Arthur, A Johnson, J Nazroo, K Fenton; on behalf of the SONHIA collaboration group J. Ainsworth, J. Anderson, M. Chikohora, A. Fakoya, I. Fakoya, A. Hughes, E. Jungmann, S. Manney, L. Muromba, N. Nwokolo, N. Panahmand, S.T. Sadiq, M. Slinn, R. Stack, A.K. Sullivan

**Acquisition of HIV infection in Africans resident in London: how much and how to assess**

*AIDS* 2008; in press



Di Lorenzo G, Kreuter A, Di Trolio R, Guarini A, Romano C, Montesarchio V, Brockmeyer NH, De Placido S, Bower M, Dezube BJ

**Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi's Sarcoma: A Multicenter Study**

*J Invest Dermatol.* 2008 Jan 10

Stebbing J, Powles T, Bower M

**AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count**

*AIDS.* 2008; 22(4):551-2

Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study

**Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?**

*AIDS.* 2008 Jan 30;22(3):349-56.

Coyne KM, Barton SE, Smith NA, Cohen CE

**Azithromycin without a prescription increases access and choice for patients**

*Int. J. STD & AIDS* 2008;19:870

Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales N & Webb A on behalf of the AIDS malignancy subcommittee

**British HIV association guidelines for HIV-associated malignancies 2008.**

*HIV Med* 2008, 9: 336-388 2008

Gazzard BG; BHIVA Treatment Guidelines Writing Group

**British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.**

*HIV Med.* 2008 Oct;9(8):563-608.

Stebbing J, Wood C, Atkins M, Bukowski R, Litwin S, Bower M, Parsa A, Levitsky H

**Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments**

*Cancer.* 2008;112(5):955-961

Steel A, John L, Shamji MH, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.

**CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy**

*HIV Med.* 2008 Feb;9(2):118-25

J. Krell, M. Tuthill, V. Campbell, M. Nelson, P. Holmes, T. Powles, J. Stebbing, M. Bower

**Cellular immunity following chemotherapy for systemic AIDS related non Hodgkin's lymphoma (NHL)**

*HIV Medicine* 2008, 9 (Suppl 1): 24.2008

Teague A, Scott C, Youngstein T, Bower M, Gazzard B & Nelson M

**Clinical experience with raltegravir (MK-0518 or Isentress), with an optimised background regimen in highly treatment experienced patients**

*HIV Medicine* 2008, 9 (Suppl 1): 17.

Holmes P, Nelson M, Bower M, Gazzard B & Barton S.

**Coding and the clinician.**

*HIV Medicine* 2008, 9 (Suppl 1): 46.

Daniels RH, Gazzard BG, Holmes P, Scourfield A, Bower M, Nelson M

**Comparing the efficacy of Truvada® and Kivexa® combination therapy in HAART-naive individuals with different viral loads.**

*Journal of the International AIDS Society* 2008, 11 (Suppl 1):P14 (10 November 2008)

Gazzard BG.

**Controversies in current treatment guidelines.**

*J HIV Ther.* 2008 Mar;13(1):1-3.

Winters B, Montaner J, Harrigan PR, Gazzard B, Pozniak A, Miller MD, Emery S, van Leth F, Robinson P, Baxter JD, Perez-Elias M, Castor D, Hammer S, Rinehart A, Vermeiren H, Van Craenenbroeck E, Bachelier L.

**Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.**

*J Acquir Immune Defic Syndr.* 2008 May 1;48(1):26-34.

Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group.

**Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?**

*AIDS.* 2008 Nov 12;22(17):2381-90.

## 2008 continued

Mihailidis C, Dunn D, Pillay D, Pozniak A

**Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy**

*AIDS. 2008 Jan 30;22(3):427-30*

Rosignoli G, Liptrott N, Imani N, Bower M, Gotch F & Owen A

**Effect of PD1.3 single nucleotide polymorphism on CD4 and CD3 T cell counts in HAART-treated chronic HIV-1+ patients.**

*HIV Medicine 2008, 9 (Suppl 1): 8.*

Schöller-Gyüre M, Boffito M, Pozniak AL, Leemans R, Kakuda TN, Woodfall B, Vyncke V, Peeters M, Vandermeulen K, Hoetelmans RM.

**Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.**

*Pharmacotherapy. 2008 Oct;28(10):1215-22.*

Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS, Imami N.

**Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up**

*J Immune Based Ther Vaccines. 2008; 6:7*

Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett-Smith H.

**Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfecting patients receiving lamivudine as part of antiretroviral therapy.**

*AIDS. 2008 Sep 12;22(14):1779-87.*

Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V

**Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection**

*AIDS. 2008 Jan 11;22(2):275-9*

Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ.

**Episodic sexual transmission of HIV revealed by molecular phylogenetics.**

*PLoS Med. 2008 Mar 18;5(3):e50.*

Scott C, Khatib N, Bower M, Gazzard BG, Nelson M.

**Etravirine use in clinical practice: 48-week data from a single centre cohort.**

*Journal of the International AIDS Society 2008, 11(Suppl 1):P49 (10 November 2008)*

Clumeck N, Pozniak A, Raffi F; EACS Executive Committee.

**European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults**

*HIV Med. 2008 Feb;9(2):65-71*

Asghar AK, Bower M, Holmes P, Gazzard BG, Isenman H, Nelson M

**Ezetimibe as lipid-lowering therapy for patients receiving HAART.**

*Journal of the International AIDS Society 2008, 11(Suppl 1):P248 (10 November 2008)*

Burton C, Eccles-James I, Nelson M, Bower M, Gotch F & Imani N

**Functional and phenotypic profiling of suppressive regulatory T cells in a cohort of HIV-1 Infected individuals.**

*HIV Medicine 2008, 9 (Suppl 1): 41*

Macdonald DC, Nelson M, Bower M, Powles T.

**Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era.**

*World J Gastroenterol. 2008 Mar 21;14(11):1657-1663*

Moyle G, Randell P

**HIV and Cardiovascular risk**

*Clinical Medicine 2008;8:315-8.*

Harania RS, Karuru J, Nelson M, Stebbing J.

**HIV, hepatitis B and hepatitis C coinfection in Kenya**

*AIDS. 2008 Jun 19;22(10):1221-2.*

Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ

**HIV-associated multicentric Castleman's disease**

*Am J Hematol. 2008; 83(6):498-503*

Barber TJ, Menon-Johanson A, Barton S

**How can we remove barriers to HIV testing outside of GUM setting?**

*Br J Gen Pract. 2008 May; 58 (550): 365*

Gaughan EM, Dezube BJ, Abouafia D, Bower M, Stebbing J, Powles T, Pantanowitz L

**Human immunodeficiency virus-associated renal cell carcinoma: a transatlantic case series.**

*Clin Genitourin Cancer.* 2008, 6(2):86-90

Bower M, Stebbing J, Tuthill M, Campbell V, Krell J, Holmes P, Ozzard A, Nelson M, Gazzard B, Powles T

**Immunological recovery in survivors following chemotherapy for AIDS related non Hodgkin's lymphoma.**

*Blood.* 2008 Jan 2;

Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study group.

**Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.**

*HIV Med.* 2008 Nov;9(10):883-96

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN

**Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.**

*J Infect Dis.* 2008 Apr 15;197(8):1145-55

Scott C, Grover D, Nelson M.

**Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?**

*AIDS.* 2008 May 11;22(8):989-90.

Asghar A, Bower M, Gazzard B, Holmes P, Isenman H & Nelson M.

**Lipid lowering effect of ezetimibe in patients with HAART-associated dyslipidaemias**

*HIV Medicine* 2008 9 (Suppl 1): 33.

Goodier M, Gregson J, Constantinou D, Steel A, Bower M, Gazzard B & Gotch F

**Lipopolysaccharide-induced activation of natural killer cells from HIV-1 infected individuals**

*HIV Medicine* 2008, 9 (Suppl 1): 41

Naresh KN, Rice AJ, Bower M.

**Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma**

*Am J Surg Pathol.* 2008 Jul;32(7):1006-12

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

**Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study**

*J Infect Dis.* 2008 Apr 15;197(8):1133-44

Pozniak A.

**Management of HIV: still a long way to go**

*Br J Hosp Med (Lond).* 2008 Mar;69(3):126

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

**Maraviroc for previously treated patients with R5 HIV-1 infection.**

*N Engl J Med.* 2008 Oct 2;359(14):1429-41

FM Burns, A Johnson, J Nazroo, K Fenton; on behalf of the SONHIA collaboration group (J. Ainsworth, J. Anderson, R. Arthur M. Chikohora, A. Fakoya, I. Fakoya, A. Hughes, E. Jungmann, S. Manney, L. Muromba, N. Nwokolo, N. Panahmand, S.T. Sadiq, M. Slinn, R. Stack, A.K. Sullivan.

**Missed opportunities for earlier HIV diagnosis within primary and secondary health care settings in the UK.**

*AIDS* 2008; 22:115-22.

Molina J-M, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, Thiry A, McGrath D, for the CASTLE Study Team

**Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study**

*The Lancet* 2008: 372:646-55

Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J, Schechter M.

**Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs**

*J Med Virol.* 2008;80:565-76.

## 2008 continued

Coyne, KM, Cohen CE, Smith NA, Barton SE.

**Patient-delivery partner medication**

*Int. J. STD & AIDS* 2008;19:646

Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CA; on behalf of the UK Collaborative HIV Cohort (CHIC) Study Steering Committee.

**Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.**

*HIV Med.* 2008 Jan;9(1):47-56.

Dickinson L, Boffito M, Khoo SH, Schutz M, Aarons LJ, Pozniak AL, Back DJ

**Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.**

*J Antimicrob Chemother.* 2008 Jul;62(1):161-7

Sousa M, Pozniak A, Boffito M.

**Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs.**

*J Antimicrob Chemother.* 2008 Nov;62(5):872-8. Epub 2008 Aug 18

Singh K, Dickinson L, Chaikan A, Back D, Fletcher C, Pozniak A, Moyle G, Nelson M, Gazzard B, Herath D, Boffito M.

**Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects**

*Clin Pharmacol Ther.* 2008 Jun;83(6):867-72.

Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Pozniak A, Gazzard B, Moyle G

**Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.**

*Antivir Ther.* 2008;13(7):901-7

Boffito M, Miralles D, Hill A.

**Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and experienced patients.**

*HIV Clin Trials.* 2008 Nov-Dec;9(6):418-27.

V. Campbell, J. Krell, M. Stancliffe, M. Atkins, M. Habibi, M. Nelson, B. Gazzard, M. Bower

**Plasma HHV8 DNA viral load as a tumour marker for multicentric Castleman's disease MCD**

*HIV Medicine* 2008, 9 (Suppl 1): 7.

Moyle G, Gatell J, Perno CF, Ratanasuwan W, Schechter M, Tsoukas C.

**Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.**

*AIDS Patient Care STDS* 2008;22:459-71

El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD

**Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.**

*Ann Intern Med.* 2008 Sep 2;149(5):289-99

Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, Holodniy M, Lalezari JP, Levy Y, Mitsuyasu RT, Palella FJ, Pollard RB, Rajagopalan P, Saag MS, Salata RA, Sha BE, Choudhri S.

**Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy.**

*J Interferon Cytokine Res.* 2008 Feb;28(2):89-100

Underwood J, Scourfield A, Bell C, Harding V, Bower M & Nelson M

**Severe hepatotoxicity associated with darunavir**

*HIV Medicine* 2008, 9 (Suppl 1): 18

Byakika-Kibwika P, Lamorde M, Kalemeera F, D'Avolio A, Mauro S, Di Perri G, Ryan M, Mayanja-Kizza H, Khoo S, Back D, Boffito M, Merry C.

**Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.**

*J Antimicrob Chemother.* 2008 Nov;62(5):1113-7.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

**Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.**

*N Engl J Med.* 2008 Oct 2;359(14):1442-55

Ewings FM, Bhaskaran K, Nock, Porter K, D, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Brettle R, Johnson M, Phillips A

**Survival following HIV infection of a cohort followed up from seroconversion in the UK**

*AIDS*. 2008 Jan 2;22(1):89-95

Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team.

**Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.**

*HIV Med*. 2008 Oct;9(8):667-72.

Kavouni A, Catalan J, Brown S, Mandalia S, Barton SE

**The face of HIV and AIDS: can we erase the stigma?**

*AIDS Care*. 2008 Apr; 20 (4) 485-7

Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G.

**The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.**

*Clin Infect Dis*. 2008;46:1617-23

J.Krell, A. Bazeos, V. Campbell, V. Harding, T. Powles, J. Stebbing, S. Mandalia, M. Bower.

**The incidence of HIV-associated multicentric Castlemans disease**

*HIV Medicine* 2008, 9 (Suppl 1): 7 2008

Waters L, Nelson M, Mandalia S, Bower M, Powles T, Gazzard B, Stebbing J.

**The risks and incidence of K65R and L74V mutations and subsequent virologic responses**

*Clin Infect Dis*. 2008 Jan 1;46(1):96-100

Shah PL, Singh S, Bower M, Livni N, Padley S, Nicholson AG.

**The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer**

*J Thorac Oncol*. 2006; 1(4):324-7.

Turner C, Cohen CE, Sabin C, Tosswill J, Best J, Taylor G, de Ruiter A, Barlow D, Smith NA.

**The Seroepidemiology of HTLV-1 amongst genitourinary attendees in South East London.**

*Journal of Clinical Virology*. 2008 Oct;43(2):253-4. Epub 2008 Aug 8

Stebbing J, Ngan S, Ibrahim H, Charles P, Nelson M, Kelleher P, Naresh KN, Bower M.

**The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease**

*Clin Exp Immunol*. 2008, 154(3):399-405.

V. Campbell, J. Krell, A. Scourfield, S. Mandalia, M. Nelson, T. Powles, J.Stebbing, M. Bower

**The use of antidepressants and risk of cancer in individuals infected with the human immunodeficiency virus**

*HIV Medicine* 2008, 9 (Suppl 1): 25 2008

Cohen CE, Coyne KM, Mandalia S, Waters AM, Sullivan AK

**Time to use text reminders in genitourinary medicine clinics**

*Int J STD AIDS* 2008 Jan; 19 (1): 12-3.

Lagos D, Vart RJ, Gratrix F, Westrop SJ, Emuss V, Wong PP, Robey R, Imami N, Bower M, Gotch F, Boshoff C

**Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus**

*Cell Host Microbe*. 2008 Nov 13;4(5):470-83

Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, Grundy A, Moyle GJ

**Treatment of Altered Body Composition in HIV-Associated Lipodystrophy: Comparison of Rosiglitazone, Pravastatin, and Recombinant Human Growth Hormone**

*HIV Clin Trials* 2008;9(4):253-267

Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, Gompels M, Kinghorn G, McCarron B, Pozniak A, Tang A, Walsh J, Williams I, Gazzard B.

**Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).**

*Int J STD AIDS*. 2008 May;19(5):297-304.

United Kingdom Collaborative HIV Cohort Study, Lee KJ, Dunn D, Porter K, Bansi RG, Hill T, Phillips AN, Sabin CA, Schwenk A, Leen C, Delpech V, Anderson J, Gazzard B, Johnson M, Easterbrook P, Walsh J, Fisher M, Orkin C.

**Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.**

*AIDS*. 2008 Oct 1;22(15):1943-50.

Jones R, Nelson M, Bower M, Powles T, Mandalia S, Gazzard B, Stebbing J

**Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomes.**

*Arch Intern Med*. 2008, ;168(17):1926-7.

2008 continued

Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M

**Use of antidepressants and risk of cancer in individuals infected with HIV**

*J Clin Oncol.* 2008 May 10;26(14):2305-10

---

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

**Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen**

*AIDS.* 2008 Nov 12;22(17):2279-89.

---

Ancock B, Bower M, Gazzard BG, Nelson M

**Vitamin D deficiency in the in-patients HIV population: cause or effect?**

*Journal of the International AIDS Society* 2008, 11(Suppl 1):P116 (10 November 2008)

---

Bhattacharya R, Barton SE, Catalan J

**When good news is bad news: psychological impact of false positive diagnosis of HIV**

*AIDS Care.* 2008 May; 20(5): 560-4

---